Physician profile
Mateen Haque
NPI 1427599711
$8,573.57
in general payments reported to CMS, 2019-2025
37 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $267 · 2021: $820 · 2022: $1,256 · 2023: $1,936 · 2024: $1,971 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,718 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,717.75 |
| Education | $130.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,021.38 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $897.75 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $786.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $710.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $515.05 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.59 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $456.96 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $318.31 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $288.22 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $241.74 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $202.49 | 2020-2024 | Injectafer |
| Abbott Laboratories | $158.75 | 2021-2025 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $152.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.47 | 2022-2025 | Xifaxan, Trulance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mateen Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.